Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Dianthus Therapeutics, Inc. (DNTH : NSDQ)

• Company Description    Dianthus Therapeutics Inc. is a privately-held, clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics. Dianthus Therapeutics Inc., formerly known as Magenta Therapeutics Inc., is based in CAMBRIDGE, Mass. Number of Employees: 92

• Price / Volume Information    Yesterday's Closing Price: $103.87 Daily Weekly Monthly 20 Day Moving Average: 1,227,010 shares Shares Outstanding: 54.67 (millions) Market Capitalization: $5,678.16 (millions) Beta: 1.20 52 Week High: $107.99 52 Week Low: $18.08 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 13.43% 12.60% 12 Week 18.30% 15.06% Year To Date 152.05% 134.96%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 7 Times Square 43rd Floor - New York,NY 10036 USA ph: 929-999-4055 fax: - ir@dianthustx.com http://www.dianthustx.com

• General Corporate Information    Officers Marino Garcia - President; Chief Executive Officer and Director Alison Lawton - Chairman Ryan Savitz - Executive Vice President; Chief Financial Officer Edward Carr - Chief Accounting Officer Anne McGeorge - Director Peer Information Dianthus Therapeutics, Inc. (CORR.) Dianthus Therapeutics, Inc. (RSPI) Dianthus Therapeutics, Inc. (CGXP) Dianthus Therapeutics, Inc. (BGEN) Dianthus Therapeutics, Inc. (GTBP) Dianthus Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 252828108 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/06/26 Share - Related Items Shares Outstanding: 54.67 Most Recent Split Date: 9.00 (0.06:1) Beta: 1.20 Market Capitalization: $5,678.16 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.04 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-3.82 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 7.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/06/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 4.71 Price/Cash Flow: - Price / Sales: 4,250.12 EPS Growth vs. Year Ago Period: -3.66% vs. Previous Quarter: 40.56% Sales Growth vs. Year Ago Period: -60.19% vs. Previous Quarter: 63.03% ROE 06/30/26 - - 03/31/26 - -27.30 12/31/25 - -38.85 ROA 06/30/26 - - 03/31/26 - -25.91 12/31/25 - -36.42 Current Ratio 06/30/26 - - 03/31/26 - 29.25 12/31/25 - 13.32 Quick Ratio 06/30/26 - - 03/31/26 - 29.25 12/31/25 - 13.32 Operating Margin 06/30/26 - - 03/31/26 - -12,998.50 12/31/25 - -7,973.33 Net Margin 06/30/26 - - 03/31/26 - -12,998.50 12/31/25 - -7,973.33 Pre-Tax Margin 06/30/26 - - 03/31/26 - -12,998.50 12/31/25 - -7,973.33 Book Value 06/30/26 - - 03/31/26 - 22.06 12/31/25 - 11.41 Inventory Turnover 06/30/26 - - 03/31/26 - - 12/31/25 - - Debt-to-Equity 06/30/26 - - 03/31/26 - 0.00 12/31/25 - 0.00 Debt-to-Capital 06/30/26 - - 03/31/26 - 0.00 12/31/25 - 0.00

Powered by Zacks Investment Research ©